原发性肝癌血清标志物:机会与挑战  

Serum markers for primary liver cancer: opportunities and challenges

作　　者：任晨然 郭敏 王涛 夏机良 曾希 曹德良 REN Chenran;GUO Min;WANG Tao;XIA Jiliang;ZENG Xi;CAO Deliang(Institute of Oncology,Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer,Hengyang Medical School,University of South China,Hengyang 421001,Hunan,China)

机构地区：[1]南华大学衡阳医学院肿瘤研究所,肝癌早诊早治湖南省工程研究中心,湖南衡阳421001

出　　处：《中南医学科学杂志》2024年第3期313-317,共5页Medical Science Journal of Central South China

基　　金：国家自然科学基金(81772842);湖南省长株潭国家自主创新示范区专项资助(2018XK2106);湖南省普通高等学校科技创新团队支持项目资助[湘教通(2023)233号]。

摘　　要：原发性肝癌目前的常规筛查方法是甲胎蛋白结合腹部超声,但其灵敏度与特异度严重不足,难以满足原发性肝癌早期诊断的需求。本文总结了原发性肝癌的传统标志物以及新兴血清标志物,重点介绍了在原发性肝癌筛查与早期诊断中富有前景的新型原发性肝癌血清标志物——醛酮还原酶1B10,以期为原发性肝癌的早期诊断带来新思路。The current conventional screening method for primary liver cancer is alpha-fetoprotein combined with abdominal ultrasound,but its sensitivity and specificity are severely insufficient to meet the needs of early diagnosis of primary liver cancer.This article summarizes the traditional markers and emerging serum markers of hepatocellular carcinoma,and focus on aldo-keto reductase 1B10,a novel serum marker of primary liver cancer with great potential for early diagnosis,a promising serum marker for hepatocellular carcinoma,in order to bring new ideas for early diagnosis of primary liver cancer.

关 键 词：AKR1B10 原发性肝癌 血清标志物 液体活检 蛋白标志物 

分 类 号：R735.7[医药卫生—肿瘤]